



ROTH Capital Partners



ROTH Acts as Lead Placement Agent in GenVec, Inc. (GNVC) \$28 Million Registered Direct Offering

Client Information

GenVec, Inc. ("GenVec" or the "Company") is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade™, is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. The Company also uses its proprietary adenovector technology to develop vaccines for infectious diseases including influenza, HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2 (Source: Press Release).

Transaction Information

On January 27, 2010, GenVec announced a registered direct offering of 14,000,000 shares of its common stock and warrants to purchase 4,200,000 shares of its common stock. The shares of common stock and warrants were offered in units consisting of one share of common stock and 0.30 warrants to purchase one share of common stock at a price of \$2.00 per unit. The warrants have a term of five years and an exercise price of \$2.75 per share. The securities described above were offered by GenVec pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission. ROTH Capital Partners served as lead placement agent for the offering.

ROTH Capital Partners

ROTH is a full service investment banking firm dedicated to advising public and private emerging growth companies. Headquartered in Newport Beach, California, ROTH offers a wide array of services to both corporate and institutional clients including: initial public offerings, follow-ons, mergers and acquisitions, SPACs, PIPEs, private placements, investment research and institutional sales and trading.

For recent news about ROTH and upcoming events please visit

ROTH Press Room

ROTH Upcoming Conferences & Events

\$28,000,000



REGISTERED DIRECT
LEAD PLACEMENT AGENT

February 2010

For more information on how ROTH can help you, please contact:

Investment Banking

John Chambers

Managing Director
Head of Healthcare
Investment Banking
646-358-1901
jchambers@roth.com

Michael Margolis, R.Ph.

Managing Director
646-358-1902
mmargolis@roth.com

Warren Dunnivant II

Vice President
646-358-1903
wdunnivant@roth.com

Equity Capital Markets

Aaron Gurewitz

Head of Equity Capital Markets
949-720-5703
agurewitz@roth.com

Lou Ellis

Sr. Vice President
949-720-5739
lellis@roth.com

Nazan Akdeniz

Sr. Vice President
949-720-5740
nakdeniz@roth.com

The material, information and facts discussed in this announcement other than the information regarding ROTH Capital Partners, LLC ("ROTH") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of ROTH. Copyright 2010.

ROTH Capital Partners, LLC. | 24 Corporate Plaza, Newport Beach, CA 92660 | 800.678.9147 | www.roth.com | Member SIPC/FINRA